Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee

NCT03081806 is registered in ClinicalTrials.gov with Techfields Pharma Co. Ltd as lead sponsor.

NCT NCT03081806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03081806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind, 22-Week and 30-Week Open-label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of X0002 Spray in Relief of the Pain for Subjects With Osteoarthritis of the Knee
Lead sponsor
Techfields Pharma Co. Ltd
Phase
Phase 3
Overall status
Completed
Start date
September 24, 2021
Completion date
January 10, 2024
Enrollment
399 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

pain associated with osteoarthritis of the knee